News & Articles

New state-of-the-art facility has been designed to support PhoreMost’s phenotypic screening expertise

Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability

Lead allosteric PLK1 inhibitor to progress through preclinical and IND enabling studies

inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets

Investment to fund expansion of operations and progression of drug target pipeline